Bristol-Myers Squibb Co announced its immunotherapy Opdivo failed to meet the main goal of a late-stage trial, Reuters reported.

It was tested in patients with an aggressive form of tumor that affects the brain or the spine.

Glioblastoma multiforme (GBM) is the most common type of tumor that forms in the nervous system. Treatment usually involves surgery along with radiation therapy and chemotherapy.

Survival of patients with GBM

Opdivo, used in combination with radiation therapy, failed to extend survival in patients with glioblastoma multiforme (GBM), when compared with the chemotherapy temozolomide and radiation therapy.

Opdivo is Bristol’s growth driver and brought in $1.8 billion in first-quarter sales.

The drug is already approved as a treatment for types of skin, lung and kidney cancers, and faces fierce competition for other immunotherapies including those from rivals Merck & Co Inc and Roche Holding.